Category Archives: Hematopoiesis

Hematopoiesis News is an online publication and email newsletter that provides updates on the latest research in the fields of hematopoiesis, blood, and bone marrow disorders.
Subscribe
Hematopoiesis News is a weekly newsletter in which we curate the top publications and reviews covering the regulation, expression patterns, differentiation and characterization of hematopoietic stem cells, as well as blood and bone marrow disorders. We also feature the latest job postings and upcoming conferences in the hematopoiesis field.

Prognostic Impact of TP53 Mutation, Monosomal Karyotype, and Prior Myeloid Disorder in Nonremission Acute Myeloid Leukemia at allo-HSCT

Researchers analyzed prognostic gene mutations by targeted next-generation sequencing to identify predisposing factors for predicting overall survival at one month before transplantation. They enrolled 120 patients with nonremission acute myeloid leukemia who underwent first allogeneic hematopoietic stem cell transplantation (allo-HSCT) between 2005 and 2018.
[Bone Marrow Transplantation]
Najima, Y., Sadato, D., Harada, Y., Oboki, K., Hirama, C., Toya, T., Doki, N., Haraguchi, K., Yoshifuji, K., Akiyama, M., Inamoto, K., Igarashi, A., Kobayashi, T., Kakihana, K., Okuyama, Y., Sakamaki, H., Harada, H., & Ohashi, K. (2020). Prognostic impact of TP53 mutation, monosomal karyotype, and prior myeloid disorder in nonremission acute myeloid leukemia at allo-HSCT. Bone Marrow Transplantation, 1–13. https://doi.org/10.1038/s41409-020-01016-9 Cite
Abstract

Continue reading “Prognostic Impact of TP53 Mutation, Monosomal Karyotype, and Prior Myeloid Disorder in Nonremission Acute Myeloid Leukemia at allo-HSCT”

Bookmark

No account yet? Register

0
Share

Bone Marrow-Derived Myeloid Progenitors as Driver Mutation Carriers in High- and Low-Risk Langerhans Cell Histiocytosis

Investigators examined the CD34+c-Kit+Flt3+ myeloid progenitor population as potential mutation carrier in all langerhans cell histiocytosis disease manifestations.
[Blood]
Xiao, Y., van Halteren, A. G., Lei, X., Borst, J., Steenwijk, E. C., de Wit, T., Grabowska, J., Voogd, R., Kemps, P. G., Picarsic, J., van den Bos, C., & Borst, J. (n.d.). Bone marrow-derived myeloid progenitors as driver mutation carriers in high- and low-risk Langerhans cell histiocytosis. Blood. https://doi.org/10.1182/blood.2020005209 Cite
Abstract

Continue reading “Bone Marrow-Derived Myeloid Progenitors as Driver Mutation Carriers in High- and Low-Risk Langerhans Cell Histiocytosis”

Bookmark

No account yet? Register

0
Share

Clinical and Molecular Consequences of Fusion Genes in Myeloid Malignancies

The authors discuss the history, biologic effect, and clinical impact of fusion genes in the field of myeloid leukemias.
[Stem Cells]
Matsukawa, T., & Aplan, P. D. (n.d.). Clinical and Molecular Consequences of Fusion Genes in Myeloid Malignancies. STEM CELLS, n/a(n/a). https://doi.org/10.1002/stem.3263 Cite
Abstract

Continue reading “Clinical and Molecular Consequences of Fusion Genes in Myeloid Malignancies”

Bookmark

No account yet? Register

0
Share

Infection during the First Year in Patients Treated with CD19 CAR T Cells for Diffuse Large B Cell Lymphoma

The authors analyzed 60 patients with diffuse large B cell lymphoma treated with FDA-approved CD19 chimeric antigen receptor (CAR) T cells and report the incidence, risk factors, and management of infections during the first year after treatment.
[Blood Cancer Journal]
Wudhikarn, K., Palomba, M. L., Pennisi, M., Garcia-Recio, M., Flynn, J. R., Devlin, S. M., Afuye, A., Silverberg, M. L., Maloy, M. A., Shah, G. L., Scordo, M., Dahi, P. B., Sauter, C. S., Batlevi, C. L., Santomasso, B. D., Mead, E., Seo, S. K., & Perales, M.-A. (2020). Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer Journal, 10(8), 1–11. https://doi.org/10.1038/s41408-020-00346-7 Cite
Full Article

Continue reading “Infection during the First Year in Patients Treated with CD19 CAR T Cells for Diffuse Large B Cell Lymphoma”

Bookmark

No account yet? Register

0
Share

Anti-Abortion Ethicists and Scientists Dominate Trump’s Fetal Tissue Review Board

Research advocates were eager to learn who Health and Human Services Secretary Alex Azar would appoint to the board and to see its ideological makeup. On July 31st they got their first look as it gathered online for a one-time meeting run by the National Institutes of Health.
[ScienceInsider]
Press Release

Continue reading “Anti-Abortion Ethicists and Scientists Dominate Trump’s Fetal Tissue Review Board”

Bookmark

No account yet? Register

0
Share

Twitter Account of Embattled #MeTooSTEM Founder Suspended

Twitter has suspended the account of MeTooSTEM founder BethAnn McLaughlin after allegations emerged that the former Vanderbilt University neuroscientist fabricated the Twitter account of an apparently nonexistent female Native American anthropologist at Arizona State University who had claimed to be an anonymous victim of sexual harassment by a Harvard professor.
[ScienceInsider]
Press Release

Continue reading “Twitter Account of Embattled #MeTooSTEM Founder Suspended”

Bookmark

No account yet? Register

0
Share

LW-213 Induces Cell Apoptosis in Human Cutaneous T-cell Lymphomas by Activating PERK–eIF2α–ATF4–CHOP Axis

Researchers showed that LW-213 dose-dependently inhibited human cutaneous T-cell lymphoma cell lines with IC50 values of around 10 μM, meanwhile it potently inhibited primary leukemia cells derived from peripheral blood of T-cell lymphoma patients.
[Acta Pharmacologica Sinica]
Yu, X., Zhu, M., Wang, J., Li, H., Hu, P., Qing, Y., Wang, X., Wang, H., Wang, Z., Xu, J., Guo, Q., & Hui, H. (2020). LW-213 induces cell apoptosis in human cutaneous T-cell lymphomas by activating PERK–eIF2α–ATF4–CHOP axis. Acta Pharmacologica Sinica, 1–11. https://doi.org/10.1038/s41401-020-0466-7 Cite
Abstract

Continue reading “LW-213 Induces Cell Apoptosis in Human Cutaneous T-cell Lymphomas by Activating PERK–eIF2α–ATF4–CHOP Axis”

Bookmark

No account yet? Register

0
Share

Comparative Effects of Graphene and Molybdenum Disulfide on Human Macrophage Toxicity

M1 and M2 macrophage viability and activation were mainly found to be unaffected by few‐layer graphene and MoS2 at doses up to 50 µg mL−1.
[Small]
Lin, H., Ji, D.-K., Lucherelli, M. A., Reina, G., Ippolito, S., Samorì, P., & Bianco, A. (n.d.). Comparative Effects of Graphene and Molybdenum Disulfide on Human Macrophage Toxicity. Small, n/a(n/a), 2002194. https://doi.org/10.1002/smll.202002194 Cite
Abstract

Continue reading “Comparative Effects of Graphene and Molybdenum Disulfide on Human Macrophage Toxicity”

Bookmark

No account yet? Register

0
Share

Genmab Announces European Myeloma Network and Janssen Achieve Positive Topline Results from Phase III APOLLO Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Genmab A/S announced that the European Myeloma Network in collaboration with Janssen Research & Development, LLC reported positive results from the Phase III APOLLO study of the subcutaneous formulation of daratumumab in combination with pomalidomide and dexamethasone (Pd) versus Pd alone as treatment for patients with relapsed or refractory multiple myeloma who have previously been treated with lenalidomide and a proteasome inhibitor.
[Genmab A/S]
Press Release

Continue reading “Genmab Announces European Myeloma Network and Janssen Achieve Positive Topline Results from Phase III APOLLO Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma”

Bookmark

No account yet? Register

0
Share

FDA Approves Monjuvi® (Tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

MorphoSys AG and Incyte announced that the FDA has approved Monjuvi in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant.
[MorphoSys AG]
Press Release

Continue reading “FDA Approves Monjuvi® (Tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)”

Bookmark

No account yet? Register

0
Share

Clonal Hematopoiesis in the Inherited Bone Marrow Failure Syndromes

Scientists describe a framework by which an understanding of the processes that promote clonal hematopoiesis in inherited bone marrow failure syndromes may inform clinical surveillance strategies.
[Blood]
Tsai, F. D., & Lindsley, R. C. (n.d.). Clonal hematopoiesis in the inherited bone marrow failure syndromes. Blood. https://doi.org/10.1182/blood.2019000990 Cite
Abstract

Continue reading “Clonal Hematopoiesis in the Inherited Bone Marrow Failure Syndromes”

Bookmark

No account yet? Register

0
Share

The Impact of Donor Type on the Outcome of Pediatric Patients with Very High Risk Acute Lymphoblastic Leukemia. A Study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG

Investigators demonstrated the impact of donor type on overall results of allogeneic stem cell transplantation for very-high risk pediatric acute lymphoblastic leukemia with worse results when using mismatched donor stem cell source.
[Bone Marrow Transplantation]
Dalle, J.-H., Balduzzi, A., Bader, P., Pieczonka, A., Yaniv, I., Lankester, A., Bierings, M., Yesilipek, A., Sedlacek, P., Ifversen, M., Svec, P., Toporski, J., Gungor, T., Wachowiak, J., Glogova, E., Poetschger, U., & Peters, C. (2020). The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG. Bone Marrow Transplantation, 1–10. https://doi.org/10.1038/s41409-020-01014-x Cite
Abstract

Continue reading “The Impact of Donor Type on the Outcome of Pediatric Patients with Very High Risk Acute Lymphoblastic Leukemia. A Study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG”

Bookmark

No account yet? Register

0
Share
Share